Each film coated tablet contains Methotrexate USP 10 mg.
Meth (Methotrexate) is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, and a number of solid tumours.It is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, and lung cancer, particularly squamous cell and small cell types.It is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.It is Indicated in moderate to severe rheumatoid arthritis, malignant disease and psoriasis. It is also indicated in the management of children with active polyarticular-course juvenile idiopathic arthritis, who had as insufficient therapeutic response to, or are intolerant of adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
Each film coated tablet contains Methotrexate USP 10 mg.
Meth (Methotrexate) is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, and a number of solid tumours.It is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, and lung cancer, particularly squamous cell and small cell types.It is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.It is Indicated in moderate to severe rheumatoid arthritis, malignant disease and psoriasis. It is also indicated in the management of children with active polyarticular-course juvenile idiopathic arthritis, who had as insufficient therapeutic response to, or are intolerant of adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.